This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Announces Launch Of New Patient-to-Patient Educational Campaign For ZEVALIN® On ZEVALIN.com

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, announced today the launch of the Company's new patient campaign for ZEVALIN (ibritumomab tiuxetan) Injection for Intravenous Use, on ZEVALIN.com.

ZEVALIN.com debuts four multimedia patient stories from actual patients living with follicular lymphoma and treated with ZEVALIN. Jan W., Laura T., Michael W., and Dave S. all share their perspectives on life before cancer, diagnoses, treatment options, receiving ZEVALIN, and life today. ZEVALIN.com has been completely redesigned to also become an educational resource for patients, caregivers, and healthcare professionals seeking information on follicular lymphoma and ZEVALIN. While the overall re-launch campaign will continue to focus on physicians with "RRZ" (rituximab, rituximab, ZEVALIN), additional emphasis will be placed on direct-to-patient outreach and patient-to-patient education.

“The stories of these patients on ZEVALIN.com are very moving and reinforce the centrality of patients in the mission of our company,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. “Patients today are more empowered through education to take an active role in learning about their treatment options. These four patients and their doctors chose ZEVALIN. We hope their journeys will inspire and encourage other follicular lymphoma patients to take an active role in educating themselves. Follicular lymphoma patients deserve to understand all of their options, including how one therapeutic dose of ZEVALIN could fit into their treatment plans.”

This initiative is part of a larger patient-to-patient campaign supported by print, digital, online, and personalized patient educational programs. More than ever patients are going online to learn about their disease and treatment options. ZEVALIN.com has been redesigned in part to provide a forum for patients and caregivers to learn more from other patients living with follicular lymphoma and treated with ZEVALIN.

About ZEVALIN ® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin Lymphoma who achieve a partial or complete response to first-line chemotherapy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.54 +56.48 0.31%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs